Skip to main content
. 2020 Nov 3;10:590648. doi: 10.3389/fonc.2020.590648

Table 3.

Comparison of baseline characteristics between long- and short-term survivors in non-local group.

Variable Long-term survivors (n = 27) Short-term survivors (n = 34) P value
Age (years) 49.3 ± 14.1 45.5 ± 12.2 0.256
Gender (n, %) 0.071
Male 23/27 (85.2%) 22/34 (64.7%)
Tumor size (mm) 43.0 ± 16.0 50.0 ± 16.5 0.101
KPS score 72.9 ± 14.6 77.3 ± 12.1 0.223
SVZ involvement (n, %) <0.001
Yes 12/27 (44.4%) 30/34 (88.2%)
Extent of resection (n, %) 0.933
GTR 14/27 (51.9%) 18/34 (52.9%)
Reirradiation (n, %) 0.003
Yes 19/27 (70.4%) 11/34 (32.4%)
Re-chemotherapy (n, %) 0.482
Yes 19/27 (70.4%) 21/34 (61.8%)
Yes 2/22 (9.1%) 5/31 (16.1%)
1q polysomy (n, %) 1.0*
Yes 2/22 (9.1%) 3/31 (9.7%)
19p polysomy (n, %) 0.092
Yes 8/22 (36.4%) 5/31 (16.1%)
MGMT promoter (n, %) <0.001
Methylation 22/27 (81.5%) 9/34 (26.5%)
TERT promoter (n, %) 0.383*
Mutation 2/7 (28.6%) 8/15 (53.5%)
P53 expression (n, %) 0.117
Positive 16/21 (76.2%) 17/31 (54.8%)
EGFR expression (n, %) 1.0*
Positive 16/21 (76.2%) 24/31 (77.4%)
Ki-67 index (n, %) 0.210
High 13/27 (48.1%) 11/34 (32.4%)

SVZ, subventricular zone; KPS, Karnofsky performance scale; GTR, gross-total resection; MGMT, O6-methylguanine-DNA-methyltransferase; TERT, telomerase reverse transcriptase; EGFR, epidermal growth factor receptor.

*Fisher’s-Exact Test.

In bold: p value less than 0.05.